Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033896 | 0.85 | ALDH1A1 (0.51) | ALDH1A1HPGDTSHRFBP1MAPT | |
| SCHEMBL9112792 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDTSHRSIGMAR1MEN1 | |
| SCHEMBL10344075 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDTSHRSIGMAR1MAOB | |
| SCHEMBL9112784 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDTSHRSIGMAR1MEN1 | |
| SCHEMBL876143 | 0.78 | ALDH1A1 (0.58) | ALDH1A1HPGDTSHRSIGMAR1MEN1 | |
| SCHEMBL23298373 | 0.77 | ALDH1A1 (0.53) | ALDH1A1HPGDTSHRMAPTSIGMAR1 | |
| (Z)-1,2-Diphenylethene SCHEMBL27365779 | 0.77 | NFE2L2 (0.60) | ALDH1A1FBP1MAPTBACE1NFE2L2 | |
| SCHEMBL3202573 | 0.76 | ALDH1A1 (0.72) | ALDH1A1HPGDTSHRSIGMAR1MEN1 | |
| SCHEMBL2373020 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HPGDTSHRSIGMAR1MAOB | |
| SCHEMBL3125891 | 0.76 | ALDH1A1 (0.56) | ALDH1A1HPGDTSHRSIGMAR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | ALDH1A1 2057/4885HPGD 3202/4885TSHR 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.